• TIBOT Technologies

  Participated · Equity · Oct 2019

  Tibot Technologies designs autonomous robots (Spoutnic and Spoutnic NAV) that circulate poultry houses to stimulate flock activity, reduce floor eggs, scrape and aerate litter, and improve feed conversion and bird health. The company emphasizes field-driven product development and sells robot fleets to major poultry players and individual growers. Tibot reports it already generates 35% of its revenue in North America and has a small core team that operated the recent fundraise with six people. The startup plans to use new capital to hire in sales, marketing, and operations to support growth and expand in priority markets in the US and Canada. Customers named in the article include Hubbard, Le Helloco, Agrial, LDC, Prodavi, and ISHII. The company presents its solutions as responses to rising animal-welfare standards and workforce shortages in poultry production.

• Biosency

  Led · Equity · Mar 2019

  Founded in July 2017 and based in Rennes, BIOSENCY develops connected medical devices and AI analytics for chronic respiratory pathologies. Its core product, Bora care®, pairs a French-made wristband with a cloud platform that captures SpO2, respiratory rate, heart rate and activity; the integrated BVS3 algorithm predicts COPD exacerbations (86% detection, ~3 days ahead, 9% false positive). The company recently launched Bora flow to monitor patients on non-invasive ventilation, and has provisional ANS certification and HAS certification; remote-monitoring reimbursement in France has been available since July 1, 2023. BIOSENCY is preparing a multicentre clinical trial (AUSTRAAL) supported by Bpifrance to demonstrate that its predictive algorithms reduce hospital time and improve care organization and quality of life. The team comprises 34 employees and a scientific council of five pulmonologists. Financially, BIOSENCY has raised €21M since inception (€14M dilutive funding and €7M in research grants) and reports international expansion and positive clinical results. BiOSENCY develops a medical telemonitoring device and an AI-driven analytics platform (BORA Analytics) aimed at predicting and preventing exacerbations in chronic respiratory failure patients, especially those with COPD. The device measures continuous cardio-respiratory parameters in real-life settings and the AI is designed to predict exacerbations 2–5 days before an acute episode. The company was created in July 2017 and, 18 months after founding, the team comprised 15 people supported by a scientific council of six COPD pulmonology experts. BiOSENCY collaborated with CEA Leti in developing its solution. Using the new funding the company plans to commercialize its telemonitoring solution, develop intelligent algorithms for reliable COPD exacerbation prevention, and run the associated clinical study. The company also benefits from non-dilutive support and recognition from Bpifrance, the Brittany region and the French Ministry of Higher Education, Research and Innovation (i‑Lab laureate).

No current team members are available.